Straits Times Index
3,426.47 -3.98 (-0.12%) Nikkei
37,667.41 -202.10 (-0.53%) Hang Seng
17,021.31 +16.34 (+0.10%) FTSE 100
8,285.71 +99.36 (+1.21%) Bitcoin USD
67,972.82 +921.95 (+1.37%) CMC Crypto 200
1,375.14 +44.53 (+3.35%)
Spruce Biosciences, Inc. (SPRB)
After hours:
| Previous close | 0.5448 |
| Open | 0.5442 |
| Bid | 0.5447 x 200 |
| Ask | 0.5504 x 100 |
| Day's range | 0.5401 - 0.5548 |
| 52-week range | 0.5030 - 5.9500 |
| Volume | |
| Avg. volume | 494,891 |
| Market cap | 22.475M |
| Beta (5Y monthly) | 2.42 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.1200 |
| Earnings date | 12 Aug 2024 - 16 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.50 |
Business WireSpruce Biosciences Recognized as a Bay Area Best Place to Work
SOUTH SAN FRANCISCO, Calif., June 06, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, announced that the San Francisco Business Times and the Silicon Valley Business Journal have recognized the company as a Best Place to Work in 2024.
BenzingaNano-Cap Spruce Biosciences Collaborates With HMNC Brain Health To Develop Treatment for Major Depressive Disorder
Spruce Biosciences Inc. (NASDAQ:SPRB) and HMNC Brain Health GmbH have collaborated to develop Spruce’s investigational product candidate, tildacerfont, and HMNC’s companion diagnostic, the proprietary Cortibon Genetic Selection Tool for major depressive disorder (MDD). Spruce Biosciences is a late-stage biopharmaceutical company developing its wholly-owned product candidate, tildacerfont, for classic congenital adrenal hyperplasia, polycystic ovary syndrome, and MDD. “We believe that Cortibon ha
Business WireSpruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)
SOUTH SAN FRANCISCO, Calif. & MUNICH, June 04, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB) ("Spruce"), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, and HMNC Brain Health GmbH ("HMNC"), a global precision psychiatry biopharma company, announced today a strategic collaboration to develop Spruce’s investigational product candidate, tildacerfont, a second-generation CRF
